Treatment of overactive bladder in men: Is it really different?

Abstract

Overactive bladder (OAB) in men is a topic that is gaining increasing attention as there is a wider understanding that OAB is not a female condition. There are several treatments; however, data in male populations are lacking compared to female cohorts. The high likelihood of concomitant benign prostatic hyperplasia (BPH)and benign prostatic obstruction (BPO) adds to the complexity of the treatment algorithm. The overlap in urinary storage symptoms also makes the interpretation of the literature challenging. Articles that evaluated men with OAB and men with OAB and BPH/BPO were evaluated and assessed. Behavioral interventions can offer a significant benefit to male patients with OAB. Medical therapies that have been studied in men with OAB include anticholinergics, beta-3 agonists, and phosphodiesterase-5 inhibits. These agents can be offered in addition to alpha-blockers for men with coexisting BPH/BPO.The literature on Onabotulinumtoxin-A and neuromodulation modulation in the male population is growing and shows promising results. Male OAB is complex; however, there is a growing body of literature to help guide treatments. Many treatments are available and they haveshown considerable success.